Current research status on immune-related adverse events.
10.3760/cma.j.cn441530-20220223-00058
- Author:
Yu Wei HUA
1
;
Lin ZHAO
1
Author Information
1. Department of Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China.
- Publication Type:Review
- Keywords:
Cytotoxic T lymphocyte associated antigen-4;
Immune checkpoint inhibitors;
Immune-related adverse events;
Programmed death-1
- MeSH:
Humans;
Immunologic Factors/adverse effects*;
Immunosuppressive Agents;
Immunotherapy/adverse effects*
- From:
Chinese Journal of Gastrointestinal Surgery
2022;25(3):271-276
- CountryChina
- Language:Chinese
-
Abstract:
Immune checkpoint inhibitors have progressed rapidly over the past decade and have become one of the most promising oncology treatments. However, immune checkpoint inhibitors reduce T-cell tolerance and lead to a unique spectrum of immune-related adverse events (IRAE). IRAE can involve multiple systems, including endocrine, gastrointestinal, respiratory and skin systems and there is no predictive marker with high specificity and sensitivity. Mild IRAE can be alleviated by discontinuing immune checkpoint inhibitors while severe IRAEs require active intervention. The first-line treatment is glucocorticoids, and immunosuppressants can be considered in refractory cases. However the optimal choice of immunosuppressants is currently controversial. This review provides an overview of the epidemiology and possible mechanisms of immune-related adverse events, outlines some promising predictive biomarkers, and describes several immunotherapy-related organ toxicity and management.
